Michael John Isaacs Sells 8,386 Shares of Prothena (NASDAQ:PRTA) Stock

Prothena Corporation plc (NASDAQ:PRTA) General Counsel Michael John Isaacs sold 8,386 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $8.47, for a total transaction of $71,029.42. Following the completion of the transaction, the general counsel owned 35,745 shares of the company’s stock, valued at $302,760.15. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Prothena Stock Performance

NASDAQ:PRTA opened at $8.12 on Friday. Prothena Corporation plc has a fifty-two week low of $6.61 and a fifty-two week high of $11.80. The stock has a market capitalization of $425.11 million, a P/E ratio of -2.88, a P/E/G ratio of 1.35 and a beta of -0.31. The company’s 50-day simple moving average is $9.05 and its 200-day simple moving average is $9.42.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.91. The firm had revenue of $51.08 million for the quarter, compared to the consensus estimate of $0.81 million. Prothena had a negative net margin of 260.92% and a negative return on equity of 43.44%. On average, research analysts forecast that Prothena Corporation plc will post 0.18 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on PRTA shares. Wall Street Zen lowered shares of Prothena from a “buy” rating to a “hold” rating in a report on Saturday, July 25th. Citigroup reiterated an “outperform” rating on shares of Prothena in a report on Friday, May 8th. UBS Group reissued a “buy” rating on shares of Prothena in a research report on Friday, July 24th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Prothena in a research note on Friday, July 24th. Finally, Weiss Ratings raised Prothena from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $23.75.

Institutional Trading of Prothena

Several large investors have recently bought and sold shares of PRTA. ProShare Advisors LLC acquired a new position in Prothena during the 4th quarter valued at approximately $100,000. PDT Partners LLC purchased a new position in shares of Prothena in the fourth quarter worth $108,000. DRW Securities LLC acquired a new stake in shares of Prothena during the fourth quarter worth $114,000. Brooklyn Investment Group lifted its stake in shares of Prothena by 13.1% during the third quarter. Brooklyn Investment Group now owns 12,569 shares of the biotechnology company’s stock worth $123,000 after buying an additional 1,456 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Prothena by 571.0% during the second quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 10,815 shares during the last quarter. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.